VISEN Pharmaceuticals
HHKEX:2561Important Dates
VISEN Pharmaceuticals's next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
Share Statistics
As of December 31, 2024, VISEN Pharmaceuticals has 103.54M shares outstanding.
| Shares Outstanding | 103.54M |
Financial Position
As of December 31, 2024, VISEN Pharmaceuticals maintains a current ratio of 4.26, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.26 |
| Quick Ratio | 3.90 |
| Debt / Equity | 0.98 |
Stock Price Statistics
HKDAs of the close on October 22, 2026, VISEN Pharmaceuticals's stock has declined approximately 58.41% over the past 52 weeks. The 50-day moving average sits at 19.16, while the 200-day moving average is 24.63.
| 52-Week Price Change | -58.41% |
| 50-Day Moving Average | 19.16 |
| 200-Day Moving Average | 24.63 |
Balance Sheet
HKDAs of December 31, 2024, VISEN Pharmaceuticals holds 216.66M in cash and equivalents against 2.51M in total debt, resulting in a net debt position of -216.66M. Total book value stands at 256.70M, with working capital of 181.33M providing operational flexibility.
| Cash & Cash Equivalents | 216.66M |
| Total Debt | 2.51M |
| Net Debt | -216.66M |
| Equity (Book Value) | 256.70M |
| Book Value Per Share | 2.48 |
| Working Capital | 181.33M |
Cash Flow
HKDThese figures cover the twelve months ended December 31, 2024.
| Capital Expenditures | -183,045.16 |